Primary prophylaxis with pegfilgrastim in patients with newly-diagnosed diffuse large B-cell lymphoma: propensity score and instrumental variable analyses

References

• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–242.
   PubMed Web of Science ®Google Scholar
• Westin EH, Longo DL. Lymphoma and myeloma in older patients. Semin Oncol. 2004;31(2):198–205.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258–2266.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices . J Clin Oncol. 2003;21(24):4524–4531.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale DC, Friedberg J, et al. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol. 2004;22(21):4302–4311.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale DC, Culakova E, et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2013;24(10):2475–2484.
   PubMed Web of Science ®Google Scholar
• Vose JM, Crump M, Lazarus H, et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol. 2003;21(3):514–519.
   PubMed Web of Science ®Google Scholar
• Grigg A, Solal-Celigny P, Hoskin P, et al. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin’s lymphoma. Leuk Lymphoma. 2003;44(9):1503–1508.
   PubMed Web of Science ®Google Scholar
• Kubo K, Miyazaki Y, Murayama T, et al. A randomized, double blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma. Br J Haematol. 2016;174(4):563–570.
   PubMed Web of Science ®Google Scholar
• Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index: a simple index of independence useful in scoring improvement in the rehabilitation of the chronically ill. Maryland State Med J. 1965;14:61–65.
   PubMedGoogle Scholar
• Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317(17):1098
   PubMed Web of Science ®Google Scholar
• Charlson M, Pompei P, Ales K, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550–560.
   PubMed Web of Science ®Google Scholar
• Tsugawa Y, Kumamaru H, Yasunaga H, et al. The association of hospital volume with mortality and costs of care for stroke in Japan. Med Care. 2013;51(9):782–788.
   PubMed Web of Science ®Google Scholar
• Williams RL. A note on robust variance estimation for cluster-correlated data. Biometrics. 2000;56(2):645–646.
   PubMed Web of Science ®Google Scholar
• VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268–274.
   PubMed Web of Science ®Google Scholar
• Baiocchi M, Cheng J, Small DS. Instrumental variable methods for causal inference. Stat Med. 2014;33(13):2297–2340. 15
   PubMed Web of Science ®Google Scholar
• Terza JV, Basu A, Rathouz PJ. Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling. J Health Econ. 2008;27(3):531–543.
   PubMed Web of Science ®Google Scholar
• Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14(1):29–35.
   PubMed Web of Science ®Google Scholar
• Yang BB, Kido A, Shibata A. Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy. Pharmacotherapy. 2007;27(10):1387–1393.
   PubMed Web of Science ®Google Scholar
• Yang BB, Kido A. Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet. 2011;50(5):295–306.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015;33(28):3199–3212.
   PubMed Web of Science ®Google Scholar
• Pinto L, Liu Z, Doan Q, et al. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2007;23(9):2283–2295.
   PubMed Web of Science ®Google Scholar
• Cooper KL, Madan J, Whyte S, et al. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. 2011;11:404.
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Kusano Y, Nishihara A, et al. Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2). Support Care Cancer. 2020;28(2):571–579. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Apro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8–32.
   PubMed Web of Science ®Google Scholar